DNTH
NASDAQ
US
Dianthus Therapeutics, Inc. - Common Stock
$86,00
▲ +$1,44
(+1,70%)
Vol. 880K
3
Punteggio di Qualità
fail
Ricavi ✗
Utile netto ✗
>IPO ✗
Cap. mercato
$1.8B
ROE
-33,0%
Margine
-4104,8%
D/E
0,00
Beta
1,57
52W
$13–$45
Consenso Wall Street
22 analisti · Apr 202610
Acquisto forte
11
Compra
1
Mantieni
0
Vendi
0
Vendita forte
95,5%
Rating Compra
Grafico dei Prezzi
Titoli simili
CELC
Celcuity Inc
$4.6B
TGTX
TG Therapeutics Inc
P/E 10,6
$4.7B
APLS
Apellis Pharmaceuticals Inc
P/E 70,7
$3.2B
IMVT
Immunovant Inc
$5.1B
APGE
Apogee Therapeutics Inc
$5.2B
FOLD
Amicus Therapeutics Inc
$4.4B
VKTX
Viking Therapeutics Inc
$4.0B
ACAD
ACADIA Pharmaceuticals Inc
P/E 17,3
$4.5B
SYRE
Spyre Therapeutics Inc
$2.5B
LEGN
Legend Biotech Corp
$4.0B
Utili
Tasso di battuta: 50,0%
Prossimo report
Mag 11, 2026
Stima EPS: $-1,08
| Trimestre | EPS Stimato | EPS Effettivo | Sorpresa |
|---|---|---|---|
| Mar 2026 | $-1,08 | — | — |
| Dic 2025 | $-1,10 | $-1,43 | $-0,33 |
| Set 2025 | $-0,88 | $-0,97 | $-0,09 |
| Giu 2025 | $-0,89 | $-0,88 | +$0,01 |
Ricavi e utili trimestrali
| Trimestre | 2024-0… | 2024-1… | 2025-0… | 2025-0… | 2025-0… |
|---|---|---|---|---|---|
| Ricavi | $2.2M | $1.3M | $1.2M | $193K | $396K |
| Utile netto | -$25.2M | -$28.4M | -$29.5M | -$31.6M | -$36.8M |
Trend fondamentali
| Metrica | 2025-06-30 | 2025-09-02 | 2025-10-02 | 2025-11-03 | 2025-12-03 | 2026-01-02 |
|---|---|---|---|---|---|---|
| ROE (TTM) | -34.7% | -34.7% | -34.7% | -34.7% | -33.0% | -33.0% |
| P/E (TTM) | — | — | — | — | — | — |
| Net Margin | -16388.1% | -2364.1% | -2364.1% | -2364.1% | -4104.8% | -4104.8% |
| Gross Margin | — | — | — | — | — | — |
| D/E Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 13.12 | 13.12 | 13.12 | 13.12 | 17.35 | 17.35 |
Rapporti chiave
ROA (TTM)
-31,1%
P/S (TTM)
574,05
P/B
1,8
EPS (TTM)
$-3,48
CF/Share
$-14,53
52W High
$45,46
52W Low
$13,37
$13,37
Intervallo 52 settimane
$45,46
Salute finanziaria
Flusso di cassa libero
-$30.6M
Debito netto
-$54.7M
Liquidità
$56.0M
Debito totale
$1.3M
Aggiornato al Set 30, 2025
Як DNTH виглядає на тлі конкурентів у Biotechnology?
Група порівняння: Micro-cap Biotechnology (All) · 528 компаній
Оцінка DNTH vs аналоги Biotechnology
P/E
—
▼
0%
sotto
peer
(18,8)
vs Peer
vs Settore
Sottovalutato
P/S
574,1
▲
4367%
sopra
peer
(12,9)
vs Peer
vs Settore
Sopravvalutato
P/B
1,8
▼
26%
sotto
peer
(2,5)
vs Peer
vs Settore
Più costoso
Дивідендна дохідність
—
▼
0%
sotto
peer
(0,0%)
vs Peer
vs Settore
Rendimento basso
Прибутковість DNTH vs аналоги Biotechnology
ROE
-33,0%
▲
51%
sopra
peer
(-67,3%)
vs Peer
vs Settore
Sotto media
Net margin
-4104,8%
▼
1331%
sotto
peer
(-286,8%)
vs Peer
vs Settore
Debole
Валова маржа
—
▼
0%
sotto
peer
(78,6%)
vs Peer
vs Settore
In linea
ROA
-31,1%
▲
33%
sopra
peer
(-46,7%)
vs Peer
vs Settore
Sotto media
Фінансове здоровʼя DNTH vs аналоги Biotechnology
D/E ratio
0,0
▼
0%
sotto
peer
(0,0)
vs Peer
vs Settore
Debito basso
Поточна ліквідність
17,4
▲
291%
sopra
peer
(4,4)
vs Peer
vs Settore
Liquidità forte
Beta
1,6
▲
62%
sopra
peer
(1,0)
vs Peer
vs Settore
Più volatile
Радар фундаменталів DNTH
DNTH
Mediana peer
Industria
DNTH прибутковість vs борг
Розмір бульбашки = капіталізація · X = чиста маржа · Y = D/E ratio
DNTH vs аналоги: ключові метрики
Attività insider
NeutralAcquisti
0
Vendite
0
SOTEROPOULOS PAULA
Director · Mar 24
27594 shs
SOTEROPOULOS PAULA
Director · Mar 24
27594 shs
GARCIA MARINO
Chief Executive Officer · Mar 16
65292 shs
CARR EDWARD
Officer · Mar 12
43682 shs
GARCIA MARINO
Chief Executive Officer · Mar 12
122918 shs
RANDHAWA SIMRAT
Officer · Mar 12
33830 shs
CARR EDWARD
Officer · Mar 12
43682 shs
GARCIA MARINO
Chief Executive Officer · Mar 12
122918 shs
RANDHAWA SIMRAT
Officer · Mar 12
33830 shs
Ultimo 90 giorni
Principali azionisti
Top 5: 35,06%FMR, LLC
14,46%
$521.8M
Wellington Management Group…
5,63%
$203.1M
Octagon Capital Advisors LP
5,43%
$196.1M
Fairmount Funds Management …
4,81%
$173.4M
Avidity Partners Management…
4,73%
$170.7M
Aggiornato al Dic 31, 2025